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Summary 
 
The genome of the pathogen Mycobacterium tuberculosis contains five copies of the ESAT-6 
(ESX) gene cluster region, which encodes for a novel type VII secretion system.  These gene 
cluster regions, which are directly involved in pathogenicity and phagosomal escape, contain 
genes encoding exported T-cell antigens ESAT-6 and CFP-10. The mechanism of action of 
the ESX secretion system however, remains largely unknown.  This study focused on ESX 
gene cluster region 4 (ESX-4), which has been shown to be the most ancestral region and is 
also present in other species of Mycobacteria and even in other high G+C Gram-positive 
bacteria, such as Corynebacterium diptheriae and Streptomyces coelicolor.   
 
This project aimed to investigate the protein-protein interactions of ESX-4 of M. tuberculosis 
in the model organism Mycobacterium smegmatis by means of Mycobacterial Protein 
Fragment Complementation (M-PFC).  M-PFC is a two-hybrid technique which employs two 
cloning vectors, pUAB300 (conferring resistance to hygromycin B) and pUAB400 (conferring 
resistance to kanamycin).  Genes of interest are cloned into these vectors and co-transformed 
into the model organism M. smegmatis after which it is expressed as fusion proteins.  
Interaction of the proteins allows selective growth on a medium containing the antibiotic 
trimethoprim.  Various interactions were identified throughout this region, including self-
interactions as well as the expected interaction between the ESAT-6 and CFP-10 protein 
family members esxT and esxU.  Since this region is ancestral, ESX-4 provides the basic 
model of the mechanism of secretion of the type VII secretion system.  Many similarities were 
apparent when the interactions identified for ESX-4 were compared to the interactions 
previously identified in ESX-3.   
 
Interactions identified by means of M-PFC provide a basis for the further study of the 
structure of this secretion system, and should be confirmed by means of other techniques, such 
as co-immunoprecipitation.  Despite the ability of M-PFC to identify protein-protein 
interactions in a mycobacterial system, and thus overcoming some of the limitations of the 
classical yeast two-hybrid model, it must still be regarded as a fishing experiment for potential 
interactions. 
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A further aim of the project was to construct a knock-out of ESX-4 in the model organism M. 
smegmatis, which contains three ESX regions, namely ESX-1, -3 and -4.  Homologous 
recombination proved to be an effective technique for the construction of the knock-out, also 
indicating that ESX-4 is not essential for in vitro growth of M. smegmatis.  The knock-out 
strain showed no morphological differences to the wild type strain of M. smegmatis.  The 
knock-out strain will in future be compared to the wild type strain in various functional studies 
in order to determine the function of the ancestral ESX region.        
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Opsomming 
 
Die genoom van die patogeen Mycobacterium tuberculosis bavat vyf kopieë van die ESAT-6 
geen groep gebiede wat kodeer vir ‘n unieke tipe VII sekresie sisteem.  Die geen groep 
gebiede, wat direk betrokke is by patogenisiteit en fagosomale ontsnapping, bevat gene wat 
kodeer vir die gesekreteerde T-sel antigene ESAT-6 en CFP-10. Die meganisme van die ESX 
sekresie sisteem is egter steeds tot ‘n groot mate onbekend.  Hierdie studie het gefokus op die 
ESX geen groep gebied 4 (ESX-4), wat voorheen bepaal is om die vroegste kopie van die 
gebied te wees en wat ook in ander species van Mikobakterieë en hoë G+C Gram-positiewe 
bakterieë, soos Corynebacterium diptheriae en Streptomyces coelicolor, voorkom. 
 
Hierdie projek was daarop gemik om die proteïen-proteïen interaksies van ESX-4 van M. 
tuberculosis in die model organisme Mycobacterium smegmatis te ondersoek deur middel van 
Mikobakteriële Proteïen Fragment Komplementasie (M-PFK).  M-PFK is ‘n twee-hibried 
tegniek wat van twee kloningsvektore, naamlik pUAB300 (wat weerstand teen hygromycin B 
bied) en pUAB400 (wat weerstand teen kanamycin bied) gebruik maak.  Gene van belang 
word in die vektore ingekloneer en in die model organisme, M. smegmatis geko-transformeer, 
waarna dit as fusieproteïene uitgedruk word.  Indien ‘n interaksie tussen die proteïene 
plaasvind, sal selektiewe groei op ‘n medium wat die antibiotikum trimethoprim bevat, 
waargeneem word.   
 
Verskeie interaksies is in hierdie gebied geïdentifiseer, insluitende self-interaksies, sowel as 
die verwagte interaksie tussen die ESAT-6 en CFP-10 proteïen familielede esxT en esxU.  
Aangesien hierdie gebied die vroegste kopie is, bied ESX-4 die basiese model vir die 
meganisme van sekresie van die tipe VII sekresie sisteem.  Wanneer interaksies wat vir ESX-4 
geïdentifiseer is met die wat voorheen vir ESX-3 geïdentifiseer is vergelyk word is daar 
heelwat ooreenkomste. 
 
Interaksies wat deur middel van M-PFK geïdentifiseer is, verskaf ‘n basis vir die vêrdere 
studie van interaksies van hierdie gebied, en sal bevestig moet word deur gebruik te maak van 
aanvullende tegnieke, soos ko-immunopresipitasie.  Ten spyte van die vermoë van M-PFK om 
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proteïen-proteïen interaksies in ‘n mikobakteriële sisteem, wat dus sommige van die 
beperkings van die klassieke gis twee-hibriedmodel oorkom, te bestudeer, behoort dit steeds 
as ‘n voorlopige metode van identifikasie beskou te word. 
 
‘n Vêrdere doel van die projek was om ‘n uitslaanmutant van ESX-4 in die model organisme 
M. smegmatis, wat drie van die ESX gebiede, naamlik ESX-1, -3 en -4 bevat, te skep.  
Homoloë rekombinasie is bewys om ‘n effektiewe tegniek te wees vir die skep van ‘n 
uitslaanmuntant en het daarop gedui dat ESX-4 nie essensieel is vir die in vitro groei van M. 
smegmatis nie.  Die uitslaanstam het ook geen morfologiese verskille getoon teenoor die 
oorspronklike stam nie.  Die uitslaanmutant sal in die toekoms gebruik word in ‘n 
verskeidenheid funksionele studies waar dit vergelyk sal word met die oorspronklike stam, ten 
einde die funksie van die vroegste ESX-gebied te bepaal.  
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BACKGROUND  
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1.1 Brief History of Tuberculosis 
 
The pathogen Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has been 
present in humans since antiquity.  Bone finds provide the earliest evidence for tuberculosis in 
man and animals, with examples of spinal TB (Pott’s disease) dating back to about 8000 BC 
(Herzog,  1998).  The frequency of Egyptian skeletons revealing tubercular deformities are 
high, which suggests that the disease was common amongst the populations of the time.  
Similarly, deformed bones have been found in Neolithic sites in Italy and Denmark and 
countries in the Middle East.  This archaeological evidence suggests that TB was prevalent 
throughout the world approximately 4000 years ago (Smith,  2003). 
 
Thanks to new developments in the molecular analysis of ancient mycobacterial DNA, further 
advancements have been made in the detection and characterization of Mycobacterium 
tuberculosis.  Recently, DNA from five M. tuberculosis genetic loci was detected in bone 
samples from a woman and infant who were buried together in a Neolithic settlement in the 
Eastern Mediterranean, dating from 9250 – 8160 years ago (Hershkovitz et al.,  2008).  
Furthermore, molecular analysis based on the amplification and verification of the M. 
tuberculosis complex insertion sequence IS6110 was conducted on bone samples from an 
ancient Egyptian population.  Analysis of samples from Upper Egypt (2120 – 500 BC) and the 
necropolis of Abydos (3000 BC) suggests that the occurrence of M. tuberculosis was 
relatively frequent in ancient Egypt (Zink et al.,  2001). 
 
It is speculated that the first literature mentioning TB was that formulated by the Babylonian 
monarch Hammurabi between 1948 and 1905 BC and is engraved in cuneiform script on a 
stone pillar.  This text describes a chronic lung disease, which is thought to be TB.  More 
conclusively, the Greek literature of the time of Hippocrates (460 – 370 BC) introduces the 
concept of phthisis, or consumption (other names for tuberculosis), as the most common 
disease of the period, combined with a high mortality rate.  The opinion of the time was that 
phthisis was a hereditary, rather than infectious disease, even though Aristotle (384 – 322 BC) 
believed that it was contagious. Only later Galen (131 – 201 AD) suspected the contagious 
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nature of phthisis, which then formed part of medical thinking for the next few hundred years 
(Herzog,  1998).   
 
The 17th century saw the first detailed pathoanatomical description of consumption, with 
Sylvius de la Boë of Amsterdam (1617 – 1655), being the first to describe the characteristic 
tubercles as a constant in the lungs and other organs of consumptives (Herzog,  1998). 
 
During the 19th century evidence of infectiousness began to grow.  In 1882 Robert Koch (1843 
– 1910) produced irrefutable evidence that a specific microbe is the fundamental cause of 
tuberculosis.  Shortly after that, in 1895, another important contribution to the diagnosis of TB 
was presented in the form of X-rays by Wilhelm Conrad von Röntgen (1845 – 1923).  This 
meant that the presence, development and severity of TB could be accurately monitored and 
studied for the first time (Herzog, 1998). 
 
 
1.2  The Symptoms and Treatment of Tuberculosis 
 
Tuberculosis can manifest in many forms, with pulmonary TB accounting for the vast 
majority of cases.  Pulmonary TB has previously been described as consumption and phthisis, 
both these terms are indicative of severe wasting and the coughing up of blood in later stages 
of the disease.  Spinal tuberculosis, also termed Pott’s disease, is marked by spinal deformity, 
as well as other bone defects.  A common manifestation of TB in the Middle Ages was 
scrofula, or cervical lymphadenitis, which is characterised by the swelling of lymph nodes in 
the neck.  Other forms of extra pulmonary TB include disease of the central nervous system, 
the urogenital tract, the digestive system and continuously in the form of lupus vulgaris 
(Smith,  2003). 
 
Treatment of tuberculosis is a relatively new development, considering the presence of the 
disease throughout the ages.  The first treatment for tuberculosis was suggested by Hermann 
Brehmer in the middle of the 19th century.  He suggested that TB, until then believed to be 
incurable, could be healed by open-air treatment by bringing patients to an “immune place”, a 
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region where there were no known consumptives.  With this belief he founded his sanatorium 
in Göbersdorf in 1854.  Many other sanatoria opened later in the 19th century, all of which 
adopted the strict rest cure regime suggested by Peter Dettweiler in 1893.  Even though the 
benefits of sanatorium treatment, such as the belief that high altitude was essential, can be 
debated, it did remove infectious patients from their public surroundings, as well as enforce 
rest and a sensible diet.  This regulated lifestyle improved the well-being of patients greatly, 
however, the long term results were not very encouraging (McCarthy, 2001).  Due to these 
poor long-term results, sanatorium treatment was gradually being supplemented.  In the 1930s 
these supplementary treatments included pneumothorax (as pioneered by Carlo Forlanini) and 
thoracoplasty.  These techniques produced consistently good results, including closure of 
cavities, conversion to negative sputum and well-preserved lung function (Sakula, 1983). 
 
In the early 1900s two French doctors, Calmette and Guérin were able, by means of over 200 
serial passages, to create an attenuated strain of Mycobacterium bovis, now known as BCG 
(bacille Calmette-Guérin).  BCG is still in use in children today, although the benefits of 
vaccination in adults do not produce concise data (Hsu et al., 2003).   
 
The most recent development in the treatment of tuberculosis is drug treatment in the form of 
antibiotics and antituberculous drugs.  Currently treatment for tuberculosis consists of an 
initial two month phase (Isoniazid, Rifampin, Pyrazinamide, Ethambutol), followed by a four 
month consolidation phase (Isoniazid and Rifampin) (Jerant et al., 2000).  However, drug 
resistance has become a major factor in the treatment of tuberculosis, with the occurrence of 
multi-drug resistant tuberculosis (MDR) and extensively drug resistant tuberculosis (XDR) on 
the rise.  As a result, tuberculosis is a major global health burden, causing 1.8 million deaths in 
2008 and 9.4 million TB cases in the same year (WHO, 2009).  The further risk of HIV/AIDS 
co-infection is potentially devastating, resulting in a high cost, both financially and in terms of 
lives. 
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1.3 The Evolution of the Mycobacterium tuberculosis complex 
 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is a member of the 
Mycobacterium tuberculosis complex.  The Mycobacterium tuberculosis complex consists of a 
group of species sharing 99.9% similarity at nucleotide level and identical 16S rRNA 
sequences (Brosch et al.,  2002).  Despite these similarities, which provide evidence that they 
all evolved from a common ancestor, they differ greatly in their host organism, phenotype and 
pathogenicity.  M. tuberculosis, M. africanum and M. canetti make up the human pathogens of 
the complex, while M. microti is a rodent pathogen.  M. bovis can infect a wide variety of 
mammals, including humans, whereas in the attenuated form (BCG) it is used as a vaccine, 
which rarely causes disease (Cole,  2002).  
 
It was originally thought that M. tuberculosis evolved from M. bovis, the agent of bovine 
tuberculosis, roughly 15 000 years ago, following the domestication of livestock.  This new 
organisation of living in villages, as opposed to a nomadic lifestyle, defined the Neolithic 
period and it seemed as though the animal pathogen had merely adapted itself to the human 
host (Cole,  2002).  However, whole genome sequencing of M. tuberculosis and comparative 
genomic studies have resulted in a different explanation.  M. bovis has undergone numerous 
deletions relative to M. tuberculosis, resulting in a smaller genome.  This indicates that M. 
bovis is the final member of a lineage separate from M. tuberculosis, but with a common 
progenitor (Brosch et al.,  2002). 
 
 
1.4 Phenotypic and Genomic characteristics of Mycobacterium tuberculosis 
 
All mycobacteria can be divided into two groups based on their growth rates.  So called fast 
growers will produce colonies in less than seven days when plated onto solid media, whereas 
slow growers will only form colonies in more than seven days.  In addition, fast growers are 
usually non-pathogenic and slow growers, including Mycobacterium tuberculosis, are usually 
pathogenic (Prescott et al.,  2002). 
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Mycobacterium tuberculosis is a rod-shaped, Gram-positive organism with a complex cell 
wall with very high lipid content (Prescott et al.,  2002).  The surface of the pathogen is also 
coated with a detergent labile capsule layer, which consists of non-covalently linked glycans, 
lipids and proteins (Sani et al., 2010). 
 
The complete sequencing of the genome of Mycobacterium tuberculosis reference strain 
H37Rv in 1998 heralded a new era for tuberculosis research.  The genome of M. tuberculosis 
H37Rv is approximately 4.4 x 106 bp in size and contains approximately 4000 genes (Cole et 
al.,  1998).   These 4000 genes account for 91% of the potential coding capacity of the genome 
and have a characteristically high G+C content of 65.5%.  Only around 40% of the genes have 
known functions and only 16% bear a resemblance to known proteins (Prescott et al., 2002). 
 
Analysis of the sequenced genome of M. tuberculosis has revealed several pathogenically 
important components, which include the ESX gene cluster regions. 
 
 
1.5 The ESX gene cluster regions 
 
The genome of M. tuberculosis contains five copies of the ESX gene cluster region, 
designated ESX-1 to ESX-5 (Fig 1.1).  These gene cluster regions encode for a novel secretion 
system, namely type VII secretion, which is directly involved in pathogenicity and 
phagosomal escape (Abdallah et al.,  2007).  These gene cluster regions contain genes 
encoding exported T-cell antigens, namely ESAT-6 (early secreted antigenic target of 6kDa) 
and CFP-10 (culture filtrate protein of 10kDa).  Due to this, these regions are often referred to 
as the ESAT-6 or ESX gene cluster regions (Brodin et al.,  2005).  It has also been 
demonstrated that ESAT-6 and CFP-10 form a tight 1:1 complex, which contributes to 
pathogenicity, since this complex binds to the surface of host cells, thus implying a signalling 
role (Renshaw et al.,  2002).   
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The ESX-1 secretion system is directly implicated in pathogenicity.  ESX-1, containing 
ESAT-6 and CFP-10, is located in the region of difference 1 (RD1) deletion region, which is 
absent in Mycobacterium bovis BCG vaccine strain and results in the attenuation of the 
organism (Pym et al.,  2002).   
 
In addition to ESX-1, the genome of M. tuberculosis contains four additional ESX gene 
clusters, ESX-2 to ESX-5, which are homologous to ESX-1 and also contain genes encoding 
for ESAT-6 and CFP-10 proteins (Fig 1.1).  It has been shown that ESX-4 is the most 
ancestral of all the regions, present in all other species of Mycobacteria and even in other high 
G+C Gram-positive bacteria, such as Corynebacterium diphtheriae and Streptomyces 
coelicolor (Fig 1.1) (Gey van Pittius et al.,  2001). 
 
ESAT-6 region 4 contains seven genes (Rv3444c to Rv3450c).  Sequence homology suggest 
these genes code for proteins with specific functions involved in transport, with Rv3444c 
(esxT) being an ESAT-6 like protein and Rv3445c (esxU) being a CFP-10 like protein (Fig 
1.2).  Furthermore, it has been shown that the genes present in ESX-4 are not essential for the 
in vivo survival of M. tuberculosis (Singh et al.,  2006). 
 
Studying the protein-protein interactions of these regions could provide valuable insights into 
the structure and function of these secretion systems. 
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Figure 1.1 Schematic representation of the five ESAT-6 gene cluster regions of 
Mycobacterium tuberculosis in order of duplication.    Blocked arrows indicate ORFs, as 
well as the direction of transcription.  The different colours reflect the specific gene family, 
while the lengths of the arrows reflect the relative gene length.  Black arrows indicate 
unconserved genes present in these regions.  Annotations of M. tuberculosis H37Rv genes 
according to Cole et al (1998). The Mycobacterium bovis BCG RD1 deletion region is 
indicated in ESAT-6 region 1.  Homology between ESAT-6 region 4 and the regions in 
Corynebacterium diphtheriae and Streptomyces coelicolor is also shown.  (Gey van Pittius et 
al., 2001) 
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Figure 1.2 A schematic representation of ESX-4 of Mycobacterium tuberculosis.  The 
traditional annotation of M. tuberculosis H37Rv (Cole et al., 1998) is given in bold and the 
new nomenclature, as proposed by Bitter et al (2009) is indicated in brackets.  Gene length is 
indicated on the gene and suggested functions are indicated above the genes. 
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1.6  Studying protein-protein interactions in Mycobacteria 
 
In order to study protein interactions in M. tuberculosis Singh et al. (2006) utilised a 
mycobacterial two-hybrid system, termed Mycobacterial Protein Fragment Complementation 
(M-PFC).  According to this method proteins of interest are independently fused to domains of 
murine dihydrofolate reductase (mDHFR).  Upon interaction of the proteins, functional 
reconstitution of the two mDHFR domains occurs, resulting in mycobacterial resistance 
against the antibiotic trimethoprim, thus allowing for selection (Fig 1.3).   
 
To achieve this, genes of interest are cloned into two M-PFC vectors, namely pUAB300 and 
pUAB400.  pUAB300 contains a resistance marker for the antibiotic hygromycin B, whereas 
pUAB400 contains a resistance marker for the antibiotic kanamycin.  These vectors are then 
co-transformed into Mycobacterium smegmatis.   
 
M. smegmatis is a fast-growing, non-pathogenic mycobacterium and also contains a functional 
ESX protein secretion pathway (Converse and Cox,  2005) (Fig 1.4). This provides an 
attractive model organism with the advantages of safety to researchers and the ability to study 
the protein interactions of M. tuberculosis in a closely related organism, thus overcoming 
some of the limitations of traditional two-hybrid systems where yeast is used (Singh et al.,  
2006).   
 
Using this system, Singh et al. were able to identify the well documented interaction between 
ESAT-6 and CFP-10, as well as interaction between KdpD and KdpE of M. tuberculosis.  The 
system was validated through a M. tuberculosis library screen to identify which proteins 
associated with CFP-10, by which ESAT-6 was again identified (Singh et al.,  2006).  
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Figure 1.3 Mycobacterial protein fragment complementation (M-PFC) is based on fusing 
small murine dihydrofolate reductase domains (mDHFR) independently on two possible 
interacting proteins.  If there is no interaction between the proteins (X and Y), growth on 
plates containing trimethoprim (TRIM) does not occur (a).  Upon interaction of the two fused 
proteins, functional reconstitution of the two mDHFR domains occur and mycobacterial 
resistance against TRIM will allow growth to be observed (b). 
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Figure 1.4 The three ESX regions of M. smegmatis.  Blocked arrows indicate ORFs, as well 
as the direction of transcription.  The different colours reflect the specific gene family, while 
the lengths of the arrows reflect the relative gene length.  Black arrows indicate unconserved 
genes present in these regions (Gey van Pittius et al., 2001).   
 
 
1.7 Functional studies in Mycobacteria 
 
In recent years many molecular genetic techniques have been developed to better study the 
functions of proteins in Mycobacteria.  Central to these techniques is the ability to inactivate 
genes at will, whether it is generating specific, targeted gene knock-outs or random knock-out 
mutants.  These techniques must fulfil the requirements for molecular Koch’s postulates, 
which state that, when testing whether a gene encodes a proposed function, expression of its 
functional protein must be abolished.  This specific function must be restored upon re-
introduction of the functional gene.  This provides evidence to link a pathogenic phenotype to 
a causal genotype (Machowski et al.,  2005). 
 
The development of techniques to generate targeted gene knock-outs have come a long way 
since 1990, when Snapper et al.,  (1990) described a mutant of M. smegmatis mc26 
(ATCC607), which presented increased electro transformability.  This strain, mc2155, made 
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the detection of rare events more likely, which enabled the identification of knock-out mutants 
in M. smegmatis. 
 
The pyrF gene was the first gene targeted for knock-out, since, depending on the supplement 
included in the media – uracil or 5-fluoroorotic acid (5-FOA) – it could be selected either for, 
or against.  pyrF mutants could be obtained by transforming a simple suicide plasmid, 
carrying pyrF, and disrupted by a kanamycin resistance gene (aph) into M. smegmatis (Husson 
et al.,  1990).  These initial attempts posed several technical difficulties, which included high 
frequencies of illegitimate recombination and unstable double crossover (DCO) events 
(Kalpana et al.,  1991, Aldovini et al.,  1993).    
 
In 1995 the ureC gene of M. bovis BCG was successfully inactivated by using a suicide 
plasmid delivery system.  This urease-negative mutant meant that the loss-of-function 
phenotype could be assayed in vitro (Reyrat et al.,  1995).  In an attempt to reduce the amount 
of illegitimate recombinations, a system was developed to deliver the mutant allele on a piece 
of linear DNA 40-50 kb in length.  This system was used to generate leuD mutant auxotrophs 
of M. tuberculosis (Balasubramanian et al.,  1996).   
 
In 1996, Azad et al., managed to replace the mas gene of M. bovis with the hygromycin 
cassette.  The result was mutants incapable of synthesizing mycocerosic acids.  The same 
method was employed on the pps gene cluster of M. bovis, resulting in a mutant incapable of 
synthesizing phthiocerol dimycocerosates (Azad et al.,  1997). 
 
In contrast to the techniques developed to create targeted gene knock-outs, random knock-out 
mutants can be created by random transposon mutagenesis.  This requires no prior knowledge 
of the function of the gene (McAdam et al.,  2002). 
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1.8  Construction of targeted genetic knock-outs 
 
Targeted genetic knock-outs can be constructed by means of allelic exchange based methods.  
The gene or genetic region to be disrupted is cloned into a suicide plasmid and delivered into 
cells by means of electroporation.  Two recombination events are required to create an allelic 
exchange mutant.  An initial homologous recombination event will result in a single cross over 
(SCO) recombinant.  This recombination between the chromosome and the suicide substrate 
can occur either upstream or downstream of the mutation and will contain both the wild type 
and mutant versions of the gene.  In addition, all other sequences carried on the vector will be 
retained. 
 
This is followed by a second recombination event, which will result in a double cross over 
(DCO) recombinant, which will either produce allelic exchange mutants (knock-outs) or be a 
reversion to wild type (Machowski et al.,  2005). 
 
To better identify allelic exchange mutants, two-step selection / counter-selection procedures 
have been developed.  In 1999, Pavelka and  Jacobs  refined allelic exchange methodology to 
produce mutants of two substrains of M. bovis BCG, M. tuberculosis H37Rv and M. 
smegmatis in which the lysA gene had been deleted. 
 
Primary recombinants were selected for on medium containing hygromycin.  In addition to the 
hyg gene, the suicide plasmid, pYUB657, also contained a counter selectable marker in the 
form of the sacB gene, which confers sensitivity to sucrose.  sacB is one of the most 
commonly used counter selectable markers, specifically in slow growing mycobacteria 
(Pelicic et al.,  1997).  Thus, SCOs were not only hygromycin resistant, but also sensitive to 
sucrose. 
 
In the event of a second homologous recombination event between duplicated regions, the 
plasmid, (containing the hyg and sacB genes) is lost.  This results in a DCO recombinant that 
can be either a knock-out or a reversion to wild type.  Knock-outs are able to grow on media 
containing sucrose, but die on media containing hygromycin (Pavelka and  Jacobs,  1999). 
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However, the use of sucrose resistance as a counter selectable marker is hampered by the 
occurrence of spontaneous sacB mutants, which results in false positives being present during 
counter selection on sucrose plates.  To distinguish between spontaneous sacB mutants and 
true knock-outs, the lacZ gene can be cloned into the vector.  This will allow for the selection 
of SCOs (which will be blue on a media containing X-gal) and DCOs (which will be white on 
media containing X-gal) (Parish et al.,  1999).   
 
 
1.9  Problem statement 
 
Relatively little is known about the ESX-4 secretion system of M. tuberculosis and other 
(myco)bacteria.  This region contains genes encoding for members of the family of exported 
T-cell antigens ESAT-6 and CFP-10, which in ESX-1 of M. tuberculosis is directly involved 
in the pathogenicity of the organism.  ESX-4 contains the minimal number of genes required 
for ESX secretion, thus, studying the protein-protein interaction of ESX-4 could help to set up 
a model of the machinery of this secretion system.  Since ESX-4 has also been shown to be the 
ancestral region, any information generated could provide further insights into the evolution of 
the ESX secretion systems.  In addition, deciphering the original function of the ESX secretion 
systems will lead to a better understanding of the evolution of the mechanism of 
pathogenicity.  
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1.10 Aims of the investigation 
 
This project aims to investigate the protein-protein interactions of the ESAT-6 gene cluster 
region 4 (ESX-4) of Mycobacterium tuberculosis in the model organism Mycobacterium 
smegmatis by means of Mycobacterial Protein Fragment Complementation (M-PFC) (Singh et 
al.,  2006).  These interactions can then be used to set up a model for the ESX-4 secretion 
system, as well as to identify additional substrates of the ESX-4 system. 
 
A further aim of the investigation is to study the function of ESX-4 in M. smegmatis by means 
of comparing wild type M. smegmatis to a genetic knock-out of ESX-4 in M. smegmatis.  A 
knock-out of ESX-4 in M. smegmatis can be constructed by means of homologous 
recombination techniques (Parish et al.,  1999). 
 
It is believed that an understanding of ESX-4 will enable the elucidation of the original 
function of the gene cluster, as well as to gain insights into the evolution of the ESX secretion 
system. A better understanding of the mycobacterial secretion system machinery will provide 
clues as to how to interfere in the action of pathogenicity of this organism. 
 
 
 
 
  
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS  
CHAPTER TWO 
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2.1 Bacterial strains and plasmids used in this study 
 
A wide variety of bacterial strains and plasmids were utilised throughout this study.  Some 
bacterial strains and plasmids were commercially available, while others were kind gifts, as 
indicated in Table 2.1.  The cloning vectors pUAB300 and pUAB400 were specific for the 
Mycobacterial Protein Fragment Complementation protocol and a kind gift from A Steyn.  
Vectors p2NIL and pGOAL17 were utilised in the construction of a targeted genetic knock-
out and a kind gift from E Machowski.  
 
The resistance markers, as well as origins of replication and other features of the vectors 
utilised in this study are indicated in Fig 2.1  
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Table 2.1 Bacterial strains and plasmids used in this study. 
Strains Description Reference 
 
  
Bacterial Strains   
   
E. coli K12 ER2925 Cloning host New England Biolabs 
   
E. coli JM109 Cloning host Promega 
   
M. smegmatis mc2155 Mycobacterial host strain Snapper et al., 1990 
   
M. tuberculosis H37Rv Laboratory strain of M. 
tuberculosis 
ATCC 27294 
   
Plasmids   
   
pGEM-T Easy TA cloning vector Promega 
   
p2NIL Cloning vector A kind gift from E Machowski 
   
pGOAL 17 Plasmid carrying PacI gene 
cassette carrying the LacZ and 
SacB genes 
A kind gift from E Machowski 
   
pUAB300 M-PFC cloning vector A kind gift from A Steyn 
   
pUAB400 M-PFC cloning vector A kind gift from A Steyn 
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P2NIL Vector 
 
 
pGOAL17 Vector 
 
pGEM-T Easy Vector 
 
 
M-PFC pUAB300 Vector 
 
M-PFC pUAB400 Vector 
 
Figure 2.1 Vectors used in this study. 
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2.2 Mycobacterial Protein Fragment Complementation  
 
 
2.2.1 PCR amplification and purification 
 
The DNA sequence information for Mycobacterium tuberculosis H37Rv was obtained from 
the publicly available complete genome sequence database at the Pasteur Institute website:  
http://genolist.pasteur.fr/Tuberculist.  Primers were designed for amplification of all 7 genes 
within ESX-4.  All genes had to be amplified with two different forward primers to enable in 
frame cloning into M-PFC specific vectors, pUAB300 and pUAB400 (given in Table 2.1), 
respectively.  Furthermore, the primers had to provide a cutting site for restriction enzyme 
ClaI (ATCGAT).  In addition to amplification of the full genes, both Rv3444c (ESAT-6) and 
Rv3445c (CFP-10) were also amplified in two parts due to possible toxic effects when the full 
length is expressed.  The sites where Rv3444c and Rv3445c were split are indicated on the 
modelled 3D structure of each gene, given in Figure 2.2.  Since the specific vectors can only 
efficiently carry an insert of ± 2000 bp, Rv3447c was also amplified in two parts, due to its 
size (3711 bp).  This resulted in a total of 24 constructs.  The primer sequences of each 
construct are given in Table 2.2.  For polymerase chain reaction amplification (PCR), an 
elongation time of 1 minute was used for constructs smaller than 1000 bp and an elongation 
time of 2 minutes was used for all constructs larger than 1000 bp.  FastStart Taq DNA 
polymerase (Roche) was used for all reactions.  Laboratory strain H37Rv DNA was used as a 
template.  Amplification products were run on a 1.5% agarose gel in 1 x SB buffer and 
visualised under UV light.  A molecular weight marker (100 bp; Promega) was loaded on the 
same gel to confirm that the desired size of the construct had been obtained.  All PCR 
products were purified with the Wizard SV Gel and PCR Cleanup System (Promega). 
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Fig 2.2 Modelled 3D structure of Rv3444 (ESAT-6) (A) and Rv3445 (CFP-10) (B).  The 
sites where Rv3444 and Rv3445 were split in two parts for amplification and the N-terminus 
and the C-terminus for each part are indicated by white arrows.    3D Modelling was carried 
out in SWISS-MODEL (http://swissmodel.expasy.org/)  (Arnold et al., 2006; Schwede et al., 
2003; Guex et al., 1997) 
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Table 2.2 Primer sequences of each construct according to gene and vector.  ‘F’ denotes 
the forward primer and ‘R’ denotes the reverse primer.  ‘A’ and ‘B’ refers to primers for the 
amplification of the first and second part of genes split into two parts (Rv3444c, Rv3445c and 
Rv3447c).  
 pUAB300 primers pUAB400 primers 
Gene Primer Primer sequence (5’ – 3’) Primer Primer sequence (5’ – 3’) 
Rv3444c Rv3444pUAB300 FA ATCGATCTCGACTATGAACGCAGAC Rv3444pUAB400 FA ATCGATTCGACTATGAACGCAGAC 
 
Rv3444pUAB300 FB ATCGATGCAGCAGCTCTGGACACGG Rv3444pUAB400 FB ATCGATCAGCAGCTCTGGACACGG 
 
Rv3444pUAB300 RA ATCGATCGTGTCCAGAGCTGCTG Rv3444pUAB400 RA ATCGATCGTGTCCAGAGCTGCTG 
 
Rv3444pUAB300 RB ATCGATGGAACTAGCGTGCCC Rv3444pUAB400 RB ATCGATGGAACTAGCGTGCCC 
Rv3445c Rv3445pUAB300 FA ATCGATCACGCCGTTGGTTGAACC Rv3445pUAB400 FA ATCGATACGCCGTTGGTTGAACC 
 
Rv3445pUAB300 FB ATCGATATTCATCGGCCGCATG Rv3445pUAB400 FB ATCGATTTCATCGGCCGCATG   
 
Rv3445pUAB300 RA ATCGATCTCATGCGGCCGATGAAT Rv3445pUAB400 RA ATCGATCTCATGCGGCCGATGAAT 
 
Rv3445pUAB300 RB ATCGATGGCTGATCCTCGGTCTATAGG Rv3445pUAB400 RB ATCGATGGCTGATCCTCGGTCTATAGG 
Rv3446c Rv3446pUAB300 F ATCGATCGTGAGCCCACATCGC Rv3446pUAB400 F ATCGATGTGAGCCCACATCGC 
 
Rv3446pUAB300 R ATCGATCTTCCCGGTTCAACCAAC Rv3446pUAB400 R ATCGATCTTCCCGGTTCAACCAAC 
Rv3447c  Rv3447pUAB300 FA ATCGATGCCCAGCATGAATTCAGG Rv3447pUAB400 FA ATCGATCCCAGCATGAATTCAGG 
 
Rv3447pUAB300 FB ATCGATGAGTCCCTCAGCGGTCCAC Rv3447pUAB400 FB ATCGATAGTCCCTCAGCGGTCCAC 
 
Rv3447pUAB300 RA ATCGATTGGACCGCTGAGGGACTC Rv3447pUAB400 RA ATCGATTGGACCGCTGAGGGACTC 
 
Rv3447pUAB300 RB ATCGATCGCGATGTGGGCTCACG Rv3447pUAB400 RB ATCGATCGCGATGTGGGCTCACG 
Rv3448 Rv3448pUAB300 F ATCGATGGGGAGAATGCCTACGTCTG Rv3448pUAB400 F ATCGATGGGAGAATGCCTACGTCTG 
 
Rv3448pUAB300 R ATCGATGGTACGGGACGTGGTCATG Rv3448pUAB400 R ATCGATGGTACGGGACGTGGTCATG 
Rv3449 Rv3449pUAB300 F ATCGATCATGACCACGTCCCGTACC Rv3449pUAB400 F ATCGATATGACCACGTCCCGTACC 
 
Rv3449pUAB300 R ATCGATTAGAGCCAACGCGTCAGTC Rv3449pUAB400 R ATCGATTAGAGCCAACGCGTCAGTC 
Rv3450c Rv3450pUAB300 F ATCGATGCCAGTGCCGAGCCCAG Rv3450pUAB400 F ATCGATCCAGTGCCGAGCCCAG 
 
Rv3450pUAB300 R ATCGATGCTGATGGCAACCCTGGC Rv3450pUAB400 R ATCGATGCTGATGGCAACCCTGGC 
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2.2.2 Ligation and transformation of E. coli cells 
All constructs were ligated into the commercial vector pGemT-Easy (Promega).  Ligation was 
allowed to occur overnight at 4ºC.  DNA ligations were transformed into electro competent 
Escherichia coli strain K12 ER2925, which is dam negative (dam -), preventing methylation 
of the ClaI restriction site.  Transformation of E. coli by means of electroporation was carried 
out in a Bio-Rad Gene Pulser at 2.5 kV, 200 Ohm and 25 µF.   
 
2.2.3 Media and culture conditions 
After electroporation E. coli K12 ER2925 cells were resuspended in 1ml SOC for an 
incubation period of one hour at 37ºC with shaking.  SOC [SOB (10g tryptone powder 
(Merck), 5g yeast extract (Fluka Analytical), 5g NaCl (Sigma-Aldrich) and 2.5ml 1M KCl 
(Merck) dissolved in 900ml distilled water, pH adjusted to 7 with 10M NaOH (Merck) and 
distilled water added to make up a final volume of  1 litre.)  200µl 1M Glucose and 100µl 
MgCl was added to 10ml SOB to make SOC].  After one hour of incubation at 37ºC the cells 
were plated on Luria-Bertani (LB) agar plates [10g tryptone powder (Merck), 5g yeast extract 
(Fluka Analytical), 5g NaCl (Sigma-Aldrich) and 12g bacteriological agar (Merck) dissolved 
in 1l distilled water] containing ampicillin (Roche 50µg/ml), and plates were incubated 
overnight at 37ºC (Fig 2.3).   
 
2.2.4 PCR screening and plasmid purification 
PCR screening was performed on single colonies to verify the presence of the desired insert in 
each construct.  Single colonies were picked and allowed to grow overnight at 37ºC with 
shaking in LB and ampicillin.  PCR was carried out with the same set of primers as for the 
original PCR amplification.  Upon confirmation of the constructs, cells were grown overnight 
at 37ºC with shaking in LB and ampicillin.  Plasmid DNA was extracted and purified with the 
Wizard Plus SV Miniprep DNA Purification System (Promega).  The DNA concentration was 
determined spectrophotometrically using a Nanodrop spectrophotometer (Inqaba Biotech).  
These concentrations were used to dilute the DNA to a concentration of 100ng/µl, after which 
samples were sent for sequencing.     
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Figure 2.3 Amplification and cloning of genes of ESX-4 into pGEM-T Easy.  Subsequent 
transformation into E.coli K12 ER2925 results in growth on medium containing ampicillin. 
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2.2.5 Preparation of vectors 
Cells containing the M-PFC vectors pUAB300 and pUAB400 were grown overnight at 37ºC 
with shaking.  pUAB300 containing cells were grown in LB containing hygromycin B 
(50µg/ml) and pUAB400 containing cells were grown in LB containing kanamycin (25µg/ml).  
The plasmids were purified with the NucleoBond Plasmid Purification kit (Macheney-Nagel).  
The DNA concentration was determined spectrophotometrically using a Nanodrop 
spectrophotometer (Inqaba Biotech).   
 
2.2.6 ClaI digest 
All constructs were digested with the restriction enzyme ClaI (Promega) at 37ºC for 3 hours to 
release the inserts.  Plasmid vector DNA was digested with ClaI at 37ºC for 6 hours.  All 
digests were run on a 1.5% agarose gel and the bands of the desired size were cut out and 
purified with the Wizard SV Gel and PCR Cleanup System (Promega). 
  
2.2.7 Dephosphorylation of vectors and ligation 
The vectors were dephosphorylated with shrimp alkaline phosphatase (Roche) before ligation 
could take place.  Ligation was allowed to occur overnight at 4ºC.    
 
2.2.8 Transformation of M-PFC vectors 
DNA ligations were transformed into electro competent E. coli strain JM109 at 2.5 kV, 200 
Ohm and 25 µF, after which cells were resuspended in 1ml SOC medium and allowed to 
recover for one hour at 37ºC, with shaking.  Cells containing the pUAB300 vectors were 
plated onto LB agar plates containing hygromycin (50µg/ml) and cells containing the 
pUAB400 vectors were plated onto LB agar plates containing kanamycin (25µg/ml) (Fig 2.4).  
Plates were incubated overnight at 37ºC. 
 
2.2.9 PCR screening and plasmid purification 
PCR screening was performed to verify presence and orientation of the desired construct.  
Single colonies were picked and allowed to grow overnight at 37ºC with shaking in LB and 
hygromycin (pUAB300) or LB and kanamycin (pUAB400).  PCR was carried out with the 
original set of reverse primers for each construct.  The original forward primers were 
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substituted with a sequencing primer for all pUAB300 constructs and a sequencing primer for 
all pUAB400 constructs.  The sequencing primers allowed for amplification of ±80bp of 
plasmid DNA in addition to the construct, which enabled selection of constructs in the correct 
orientation.  Cells containing constructs in the correct orientation were grown overnight at 
37ºC with shaking in LB and hygromycin (pUAB300) or LB and kanamycin (pUAB400).  
Plasmid DNA was purified with the Wizard Plus SV Miniprep DNA Purification System 
(Promega).  The DNA concentration was determined spectrophotometrically using a 
Nanodrop spectrophotometer (Inqaba Biotech).  These concentrations were used to dilute the 
DNA to a concentration of 100ng/µl, after which samples were sent for sequencing.   
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Figure 2.4 ClaI digest and cloning into M-PFC vectors, pUAB300 and pUAB400.  
Subsequent transformation into E. coli JM109 results in growth on a medium containing 
hygromycin (pUAB300) or kanamycin (pUAB400).  
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2.2.10 Transformation of M. smegmatis cells 
Transformation of M. smegmatis mc2155 was also carried out by means of electroporation in a 
Bio-Rad Gene Pulser at 2.5kV, 1000 Ohm and 25µF.  
 
2.2.11 Media and culture conditions 
After electroporation M. smegmatis mc2155 cells were resuspended in 1ml 7H9 [2.35g 7H9 
(Difco) was dissolved in 485ml distilled water. 5ml Each of 50% glucose (Kimix), 50% 
glycerol (Merck) and 20% tween-80 (Sigma) were added to cool media] and allowed to 
recover for three hours at 37°C with shaking.  After three hours of incubation cells were plated 
on 7H11 plates [19g 7H11 (BBL) was added to 970ml distilled water].  10ml each 50% 
glucose, 50% glycerol, 20% Tween-80 and appropriate antibiotics (hygromycin, 50µg/ml or 
kanamycin, 25µg/ml) were added to the media.  Plates were incubated at 37ºC for two to three 
days.  Plates were sealed in plastic bags to prevent them from drying out during their 
incubation period. 
 
2.2.12 Ziehl-Nielsen (ZN) staining 
Ziehl-Nielsen (ZN) staining was carried out on all M. smegmatis cell cultures prior to 
transformation to confirm that there is no contamination.  A smear of culture was made on a 
microscope slide and allowed to air dry.  The smear was heat fixed.  The slide was flooded 
with carbol fuchsin and heated until plenty of steam came off.  After standing for five minutes 
the slide was washed using tap water and drained.  The slide was decoloured with acid-
alcohol.  After standing for two minutes the slide was washed using tap water and drained.  
The slide was flooded with the counter stain, methylene blue, and allowed to stand for one to 
two minutes.  The slide was again washed using tap water and drained.  The slide was 
examined under a light microscope after air drying.  Mycobacterium cells can be identified as 
pink rods. 
 
2.2.13 Screening of M. smegmatis pUAB400/pUAB300 co-transformants 
In order to carry out paired screening of pUAB300 and pUAB400 ligated inserts, all 
pUAB400 (integrating vector) transformations were carried out first (Fig 2.5).  PCR screening 
was performed on single colonies to verify the presence of the pUAB400 ligated vector in M. 
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smegmatis.  Single colonies were picked and allowed to grow for two days at 37ºC with 
shaking in 7H9 liquid medium containing glucose, glycerol, Tween-80 and kanamycin.  PCR 
was carried out with the same set of primers as for the original PCR amplification to confirm 
the presence of the insert.  Upon confirmation of the presence of the vector, cell cultures were 
supplemented with 10% glycerol and stored at - 80ºC as freeze cultures.  ZN staining was 
carried out on all cultures prior to freezing to confirm absence of contamination. 
 
 
 
 
 
Figure 2.5 Transformation of pUAB400 ligated inserts into wild type M. smegmatis, resulting 
in growth on a medium containing kanamycin. 
 
  
32 
 
pUAB400 integrated M. smegmatis cultures served as stock for cultures for the subsequent 
round of pUAB300 transformations.  Electro competent pUAB400 M. smegmatis cultures 
were used for co-transformations with pUAB300 insert containing vectors.  Co-transformants 
were allowed to recover at 37°C for three hours and were then plated onto 7H11 plates 
containing hygromycin, (50µg/ml), kanamycin, (25µg/ml) and trimethoprim, (15µg/ml), and 
incubated at 37°C for 10 days (Fig 2.6).   
 
 
Co-transformants producing colonies on 7H11 plates containing hygromycin B, kanamycin, 
and trimethoprim, were considered as possible interacting partners.  Co-transformants 
containing identical inserts in both M-PFC vectors, which produced colonies on 7H11 plates 
containing hygromycin B, kanamycin, and trimethoprim were considered as self-interactions.  
Additional screening of possible interacting partners, as identified by the first screen, was also 
carried out on 7H11 plates containing an increased concentration of trimethoprim (20µg/ml 
and 25µg/ml). 
 
Co-transformants on 7H11 plates containing hygromycin, (50µg/ml), kanamycin, (25µg/ml) 
and trimethoprim, (15µg/ml), were incubated for an additional week (7 days) to determine if 
any additional growth would occur if plates were incubated beyond the 10 day screening 
period. 
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Figure 2.6 Transformation of pUAB300 ligated inserts into pUAB400 M. smegmatis stock.  
Growth on media containing kanamycin and hygromycin indicates the presence of both 
pUAB400 and pUAB300.  Subsequent culturing on media containing kanamycin, hygromycin 
and trimethoprim indicates possible interacting partners.  
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2.3 The construction of genetic knock-outs of ESAT-6 Region 4 in 
Mycobacterium smegmatis 
 
2.3.1 Construction of the knock-out construct 
The DNA sequence information for Mycobacterium smegmatis mc2155 was obtained from the 
publicly available complete genome sequence database at The Institute for Genomic Research 
(TIGR) website:  http://cmr.tigr.org/tigr-scripts/CMR/GenomePage.cgi?org=gms. 
 
For the construction of knock-outs of ESAT-6 Region 4 in Mycobacterium smegmatis by 
means of homologous recombination, a genomic region upstream and downstream of ESX-4 
in M. smegmatis, of approximately 800bp each, was PCR amplified and termed 
UpstreamMSMEG3450 and DownstreamMSMEG3444.  The primers UpstreamMSMEG3450 
(forward and reverse) and DownstreamMSMEG3444 (forward and reverse), which contain the 
restriction sites SalI and SfuI, and SfuI and HindIII respectively, were used for amplification 
(Table 2.3). 
 
The amplified regions were separately cloned into the T vector, pGEM-T Easy.  Both the 
upstream and downstream regions of ESX-4 were confirmed by sequencing.  
UpstreamMSMEG3450:pGEM-T Easy was digested with SalI (Roche) and SfuI (Roche) and 
Downstream:pGEM-T Easy was digested with SfuI and HindIII (Roche) to release the 800bp 
insert.  The digest was visualised under UV light after gel electrophoresis on a 1% agarose gel.  
The bands of desired size ( 800bp) were cut out and purified with the Wizard SV Gel and 
PCR Cleanup System (Promega).  The purified fragments were subcloned into the 
corresponding sites of the mycobacterial suicide vector, p2NIL, by means of three way 
cloning (Fig 2.7). 
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Table 2.3 Primer sequences used for the construction of the ESAT-6 Region 4 disruption 
element and screening of SCO and DCO transformants.  ‘F’ denotes the forward primer 
and ‘R’ denotes the reverse primer.  Restriction sites for knockout construction are highlighted 
in grey. (GTCGAC being the restriction site for SalI, TTCGAA the restriction site for SfuI and 
AAGCTT the restriction site for HindIII.) 
 
Primer Primer sequence (5’ – 3’) 
UpstreamMSMEG3450-F GGGGGTCGACGACGAGGAAGAGGCG 
UpstreamMSMEG3450-R GGGGTTCGAACCGTGCTGTGAACGAAACCC 
DownstreamMSMEG3444-F GGGGTTCGAACGGACTGACTCGTTGGAGCG 
DownstreamMSMEG3444-R GGGGAAGCTTCCGCGCAGTCGCCCGT 
Region 4 F1-F GAGATCGCGATGGCCATCGCC 
Region 4 F1-R CGCGTAACCGGTTGCCGTGCC 
Region 4 F2-F CCAACGCCTGGGGCGTCTGAT 
Region 4 F2-R CTGCACGGCAACCTGTCGCAG 
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Figure 2.7 Construction of disruption element and subsequent cloning into p2NIL.  ‘UpSmeg’ 
is indicative of the upstream genomic region of ESX-4 in M. smegmatis and ‘DnSmeg’ is 
indicative of the downstream genomic region of ESX-4 in M. smegmatis. 
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Figure 2.8 Digestion of pGOAL17 releases the PacI cassette containing the lacZ and sacB 
genes. 
 
The p2NIL:R4 and the pGOAL 17 vector were both digested with PacI (New England 
Biolabs).  Digestion of pGOAL 17 resulted in two fragments, namely a 2.3kb fragment, the 
vector band, and a 6.3kb fragment, which is the PacI cassette containing the lacZ and sacB 
genes, as described by Parish and Stoker (2000) (Fig 2.8).  The resultant lacZ gene encodes for 
-galactosidase activity, which allows for selection of single cross over (SCO) clones by their 
blue colour.  The sacB gene, which encodes for sucrose sensitivity, results in the killing of  
single cross over intermediate clones, as well as the selection of double cross over (DCO) 
clones, which will survive on a media containing 5% sucrose (Riedel-de Haën). 
 
The 6.3kb pGOAL17 cassette was cloned into the PacI site for p2NIL:R4 and transformed 
into electro competent JM109 E. coli, after which it was incubated for one hour at 37°C with 
shaking.  The cultures were plated onto LB agar plates, containing 25µg/ml kanamycin 
(Sigma) and 50µg/ml X-gal (Roche) and incubated overnight at 37°C.  Colonies containing 
the p2NIL:R4:pGOAL17 product was identified as blue colonies on media containing 
kanamycin and X-gal (Fig 2.9). 
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Figure 2.9 The knock-out construct, p2NILR4:pGOAL17, containing the disruption 
element, aph, lacZ and sacB genes. 
 
These colonies were picked and duplicate plated onto LB agar plates containing 5% sucrose to 
test the sensitivity of the sacB gene.  Blue colonies, that died on plates containing sucrose 
were inoculated into 500µl LB and kanamycin (Sigma) and incubated overnight at 37°C with 
shaking.  The presence of the disruption element was confirmed by PCR, resulting in a band 
of ± 1500bp when visualised under UV light after electrophoresis on a 1% agarose gel.  
Cultures confirmed to contain the construct were inoculated into 10ml LB, containing 
kanamycin (Sigma) and incubated overnight at 37°C with shaking.  Plasmid DNA was 
extracted and purified with the Wizard Plus SV Miniprep DNA Purification System 
(Promega).  
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 2.3.2 Delivery of constructs into Mycobacterium smegmatis 
Purified constructs were transformed into electro competent M. smegmatis mc2155 and 
allowed to recover for three hours at 37°C with shaking.  Transformants were plated onto LB 
agar containing 25µg/ml kanamycin (Sigma) and 50µg/ml X-gal and incubated at 37°C for 
three to four days.  A single cross over requires integration of the p2NIL:pGOAL17:R4 
construct into M. smegmatis and can be identified as blue colonies on LB agar, containing 
25µg/ml kanamycin and 50µg/ml X-gal.  Blue colonies were picked with sterile pipette tips 
and inoculated into 500µl LB, containing 25µg/ml kanamycin (Sigma) and 0.1% Tween-80 
and inoculated for two to three days at 37°C with shaking.  Single cross over transformants 
were verified by means of PCR (Fig 2.10). 
 
 
Figure 2.10 Transformation of the knock-out construct into wild type M. smegmatis.  A single 
homologous recombination event results in the formation of a single cross over (SCO). 
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Ten microlitre of confirmed single cross over culture was inoculated into 4ml LB and 0.1% 
Tween-80, lacking antibiotic to allow for a double cross over event to occur.  Inoculants were 
passaged for two to three days at 37°C with shaking.  Ten microlitre of the first passage was 
transferred into fresh 4ml LB and 0.1% Tween-80, lacking antibiotic and passaged again for 
two to three days at 37°C with shaking.  Serial passaging was continued in this manner to 
improve chances of inducing a double cross over knock-out event (Fig 2.11). 
 
After two to three days, passaged transformants were plated onto LB agar plates, containing 
5% filter sterilized sucrose and 50µg/ml X-gal and incubated for two to three days at 37°C.  
Double cross over transformants were identified as white colonies on media containing 5% 
sucrose and X-gal.  White colonies were picked with sterile pipette tips and inoculated into 
500µl LB + 0.1% Tween-80 and incubated for two to three days at 37°C with shaking.  These 
inoculates were PCR screened to establish whether a double cross over knock-out, or 
reversion to wild type had occurred.  Apparent knock-outs were confirmed by sequencing.  
 
 
Figure 2.11 Another homologous recombination event will result in the formation of a double 
cross over (DCO).  The DCO can either be a knock-out of the region, or a reversion to wild 
type.  
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3.1 Mycobacterial Protein Fragment Complementation (M-PFC) 
 
3.1.1 PCR amplification and purification 
 
All inserts were amplified from laboratory strain H37Rv genomic DNA with the primer 
sequences described in Table 2.2.  The desired size amplification products were obtained in all 
cases (Fig 3.1).  The PCR products were purified and cloned into the commercial vector 
pGemT-Easy (Promega).   
 
 
Figure 3.1 An example of amplification of the genes of ESX-4.   The PCR products of 
Rv3444cA were loaded in lanes 2 and 4, while the PCR products of Rv3444cB were loaded in 
lanes 6 and 8.  (Lanes 3, 5, 7 and 9 are no-template controls.)   
 
3.1.2 Transformation, PCR screening and Plasmid purification 
Transformations for all constructs were successful, resulting in growth on plates with LB agar 
and ampicillin.  Growth was obtained for all constructs.  Colonies were PCR screened with the 
original primer set (Table 2.2) and colonies containing constructs of the correct size were 
grown up and the plasmid DNA purified.  The determined concentration of plasmid DNA was 
used to dilute the DNA to 100ng/µl, in a final volume of 20µl and sent for sequencing.  
Correct sequencing results were obtained for all constructs. 
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3.1.3 Preparation of vectors, ClaI digest and ligation into M-PFC vectors 
DNA concentrations of 973.7ng/µl for pUAB300 and 1083.3ng/µl for pUAB400 were 
obtained from plasmid purification.  ClaI digestions of all constructs and vectors pUAB300 
and pUAB400 resulted in bands of the correct size when run on a 1.5% agarose gel (Fig 3.2).  
The DNA concentrations obtained after gel cleanup of bands were used to calculate amount of 
vector, insert DNA and water required for ligation. 
 
 
Figure 3.2 ClaI digest produced clear separation of bands of desired size.  Lanes 2 and 3 
contain Rv3444c pUAB300AB and pUAB400AB.  Lanes 4 and 5 contain Rv3444c 
pUAB300A and pUAB400A.  Rv3444c pUAB300B and pUAB400B are present in lanes 6 
and 7.  Rv3445c pUAB300AB and pUAB400AB are shown in lanes 8 and 9, with Rv3445c 
pUAB300A present in lane 10. 
 
3.1.4 Transformation, PCR screening and Plasmid purification of M-PFC vectors 
Transformation of pUAB300 and pUAB400 constructs resulted in growth on LB agar plates 
containing hygromycin and kanamycin, respectively.  PCR screening with pUAB300 and 
pUAB400 specific primers were used to confirm the presence of the desired insert, as well as 
to confirm that the insert was in the correct orientation.  Colonies containing the correct size 
constructs were grown up and the plasmid DNA purified.  The measured concentration of 
plasmid DNA was used to dilute the DNA to 100ng/µl, in a final volume of 20µl and sent for 
sequencing.  Sequencing confirmed the identity of the construct’s correctness. 
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3.1.5 Transformation of constructs into M. smegmatis 
Purified pUAB400 constructs were transformed into wild type M. smegmatis, which resulted 
in growth on 7H11 plates containing 25µg/ml kanamycin.  Colonies were PCR screened to 
confirm the presence of the desired insert and grown up to serve as stock cultures for 
subsequent transformations of pUAB300 constructs.  Transformation of pUAB300 constructs 
into pUAB400 M. smegmatis stock resulted in growth on plates containing 25µg/ml 
kanamycin and 50µg/ml hygromycin, indicating the presence of both constructs.  These 
colonies were picked and grown in liquid medium containing 25µg/ml kanamycin and 
50µg/ml hygromycin.  Growth was obtained in liquid culture for all co-transformant colonies, 
except the ten indicated in Table 3.1.  
 
Table 3.1 pUAB400/pUAB300 co-transformations unable to grow in liquid medium 
containing 25µg/ml kanamycin and 50µg/ml hygromycin. 
pUAB400 pUAB300 
3444A 3444 
3444A 3444B 
3444A 3445B 
3444A 3448 
3444B 3446 
3444B 3450 
3445B 3446 
3447B 3445 
3448 3450 
3449 3450 
 
3.1.6 Screening of M. smegmatis pUAB400/pUAB300 co-transformants 
The 134 pUAB400/pUAB300 co-transformants for which growth was observed in liquid 
medium containing 25µg/ml kanamycin and 50µg/ml hygromycin were plated onto solid 
medium containing 25µg/ml kanamycin, 50µg/ml hygromycin and 15µg/ml trimethoprim, and 
incubated at 37°C for 10 days.  Growth on plates containing 15µg/ml trimethoprim is 
indicated in Table 3.2. 
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Table 3.2 Potential interacting ESX-4 proteins, identified as growth on media containing 
15µg/ml trimethoprim. Potential interacting proteins are indicated by an “X”.  Pink shading 
indicates self-interaction and green shading indicates growth for genes in both vector 
combinations.  Grey shading indicates combinations for which growth in liquid culture was 
not observed. 
pUAB300 Construct 
pU
A
B4
00
 
C
o
n
st
ru
ct
 
 
3444 3444A 3444B 3445 3445A 3445B 3446 3447A 3447B 3448 3449 3450 
3444 X X X X X X  X     
3444A 
    X        
3444B 
            
3445 X   X         
3445A 
  X      X    
3445B X    X X  X X  X X 
3446 
  X    X X X X X  
3447A 
 X  X X   X  X   
3447B X X X  X X X X X X X X 
3448 X  X X  X   X X X  
3449 X X X X X X  X  X   
3450 X X X X X X X X X X X X 
 
 
 
3.1.7 Further screening of M. smegmatis pUAB400/pUAB300 co-transformants  
 
The 134 pUAB400/pUAB300 co-transformants that showed growth in liquid medium 
containing 25µg/ml kanamycin and 50µg/ml hygromycin were plated onto solid medium 
containing 25µg/ml kanamycin, 50µg/ml hygromycin and 20µg/ml trimethoprim, and 
incubated at 37°C for 10 days.  Growth on plates containing 20µg/ml trimethoprim is 
indicated in Table 3.3. 
 
The pUAB400/pUAB300 co-transformants were also plated onto solid medium containing 
25µg/ml kanamycin, 50µg/ml hygromycin and 25µg/ml trimethoprim, and incubated at 37°C 
for 10 days, however, extremely little growth was observed when the concentration of 
trimethoprim was increased to 25µg/ml. 
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When incubated for an additional week (7 days), no additional growth was observed for co-
transformants plated solid on medium containing 25µg/ml kanamycin, 50µg/ml hygromycin 
and 15µg/ml trimethoprim. 
 
 
 
Table 3.3 Potential interacting ESX-4 proteins, identified as growth on a medium 
containing 20µg/ml trimethoprim. Potential interacting proteins are indicated by an “X”.  
Pink shading indicates self-interaction and green shading indicates growth for genes in both 
vector combinations.  Grey shading indicates combinations for which growth in liquid culture 
could not be achieved. 
pUAB300 Construct 
pU
A
B
40
0 
C
o
n
st
ru
ct
 
 
3444 3444A 3444B 3445 3445A 3445B 3446 3447A 3447B 3448 3449 3450 
3444 X  X     X  X   
3444A 
   X         
3444B 
            
3445 X            
3445A 
            
3445B 
            
3446 
           X 
3447A 
       X     
3447B 
 X X  X X X X X X   
3448 X   X         
3449 
            
3450 X X X  X X  X X  X  
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3.2 The construction of genetic knock-outs of ESAT-6 Region 4 in 
Mycobacterium smegmatis 
 
The primers listed in Table 2.3 were used to PCR amplify ± 800bp of the upstream and 
downstream regions flanking ESAT-6 Region 4 in Mycobacterium smegmatis.  Genomic 
DNA of M. smegmatis served as template for these amplifications and PCR resulted in a ± 
800bp amplification product for the upstream region, termed UpstreamMSMEG3450 and a ± 
800bp product for the downstream region, termed DownstreamMSMEG3444. 
 
The amplified regions were cloned separately into the T vector, pGEM-T Easy.  The products 
were confirmed by sequencing.  The purified products were subcloned into the corresponding 
sites of p2NIL, the mycobacterial suicide vector, by means of three way cloning.  This 
resulted in a p2NIL:R4, which was subsequently digested with PacI (Fig B.3).  The 
pGOAL17 vector was also digested with PacI.  The resultant pGOAL17 cassette was cloned 
into p2NIL: R4, resulting in the p2NIL:pGOAL17: R4 construct. 
 
The p2NIL:pGOAL17: R4 construct was transformed into electro competent E. coli.  JM109.  
Colonies containing the p2NIL:pGOAL17: R4 construct were identified by their blue colour 
on LB agar plates containing 25µg/ml kanamycin and 50µg/ml X-gal.  These colonies were 
duplicate plated on LB agar plates containing 5% sucrose.  Blue colonies that showed sucrose 
sensitivity were inoculated into LB containing kanamycin.  The presence of the disruption 
element was confirmed by PCR and resulted in a product of ± 1400bp.  The 
p2NIL:pGOAL17:R4 plasmid was extracted and purified with the Wizard Plus SV Miniprep 
DNA Purification System (Promega). 
 
The purified constructs were transformed into electro competent M. smegmatis by means of 
electroporation.  Single cross over transformants were identified as blue colonies on LB agar 
containing 25µg/ml kanamycin and 50µg/ml X-gal and verified by means of PCR (Fig 3.3 and 
Fig 3.4). 
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Figure 3.3 Growth of transformants on LB agar containing 25µg/ml kanamycin and 
50µg/ml X-gal.  Blue colonies represent single cross over mutants. 
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Figure 3.4 Confirmation of SCO of PCR screening.  Lanes 2 and 3 contain the ± 800bp 
products of the original Upstream and Downstream primers for Region 4 (Table 2.3), 
indicating the presence of the upstream and the downstream regions, respectively.  Lane 4 
contains the product of PCR amplification with the Upstream forward primer and the 
Downstream reverse primer of Region 4 (Table 2.3), resulting in a product of ± 1600bp.  
Lanes 5-7 contain the products of PCR amplification with region 4 specific F1 and F2 primers 
(Table 2.3).  The product sizes of ± 800bp (lanes 5 and 6) and ± 1400bp confirm the SCO.  
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These single cross over mutants were passaged in LB and 0.1% Tween-80, lacking antibiotic, 
to allow for a double cross over event to occur.  Double cross over transformants were 
identified as white colonies on LB agar containing 5% filter sterilized sucrose and 50µg/ml X-
gal (Fig 3.5).  Apparent double cross over mutants were PCR screened to establish whether a 
double cross over knock-out or a reversion to wild type had occurred (Fig 3.6).  Double cross 
over knock-outs produced a product of  ± 1400bp when screened with the 
UpstreamMSMEG3450 forward and DownstreamMSMEG3444 reverse primer, but no 
products for the original UpstreamMSMEG3450 (forward and reverse) and 
DownstreamMSMEG3444 (forward and reverse) primer sets (Fig 2.3).  These double cross 
over knock outs were verified by means of sequencing. 
 
 
 
Figure 3.5 Growth of transformants on LB agar containing 5% filter sterilized sucrose 
and 50µg/ml X-gal.  White colonies represent double cross over mutants. 
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Figure 3.6 Confirmation of DCO knock-out.  Lanes 2-4: Wild type M. smegmatis; Lanes 5-
7: ESX-4 knock-out in M. smegmatis; Lanes 8-10: Water blank.  PCR amplification to 
confirm the presence of a DCO knock-out was carried out with Region 4 specific F1 and F2 
primers (Table 2.3).  Amplification with F1 (f + r) and F2 (f + r) produce products for wild 
type M. smegmatis (lanes 2 and 3), but no products for a knock-out (lanes 5 and 6).  
Amplification with F1 (f) and F2 (r) produce no product for wild type M. smegmatis (lane 4), 
but does produce a product for the knock-out (lane 7).  
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4.1 Mycobacterium Protein Fragment Complementation (M-PFC) 
 
4.1.1 M-PFC Methodology 
 
This study aimed to investigate the protein-protein interactions of the mycobacterial ESAT-6 
gene cluster region 4 (ESX-4) in the model organism Mycobacterium smegmatis by means of 
Mycobacterial Protein Fragment Complementation (M-PFC) (Singh et al.,  2006).  ESX-4 is 
the most ancestral of the mycobacterial ESAT-6 gene cluster regions of which there are five 
copies in the genome of Mycobacterium tuberculosis.  These gene cluster regions encode for a 
novel secretion system, which is directly involved in pathogenicity (Abdallah et al., 2007).    
 
ESAT-6 region 4 contains 7 genes; these include the genes for secreted T-cell antigens ESAT-
6 (esxT) and CFP-10 (esxU), as well as a probable membrane-anchored mycosin protease.  
Genes encoding a probable conserved integral membrane protein, probable conserved 
membrane protein ATPase and probable conserved membrane protein are also present.  This 
region also contains one gene that is specific to this region and is a hypothetical alanine and 
valine rich protein.  These genes were divided into 12 constructs and cloned into two M-PFC 
vectors, pUAB300 and pUAB400, resulting in a total of 24 constructs.  All constructs had to 
be put through numerous steps to ensure the correctness of the final constructs, which included 
amplification, two rounds of transformation into Escherichia coli and purification in order to 
perform sequencing.  The final constructs were co-transformed into the model organism M. 
smegmatis and screened on plates containing kanamycin, hygromycin and trimethoprim.   
 
Growth on plates containing these antibiotics were indicative of potential protein-protein 
interactions.  Many interactions were found throughout the region, including the interaction 
between ESAT-6 and CFP-10, which are known interacting partners (Renshaw et al.,  2002).  
The significance of these interactions is discussed in section 4.1.2. 
 
M-PFC provides the first experimental system for studying protein-protein interactions in 
mycobacteria, thus overcoming some of the limitations encountered when using the classical 
yeast two-hybrid (Y2H) system.  Mycobacterium tuberculosis has an extraordinarily high 
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G+C content DNA, which is not always well tolerated in an Y2H system.  Furthermore, 
interactions occur in the nucleus in the Y2H system and self activation can also occur, while 
bacterial proteins might not undergo the appropriate posttranslational modification.  M-PFC 
aids in overcoming these problems, as well as providing the potential to study protein 
associations in the mycobacterial membrane (Singh et al., 2006).   
 
This procedure also has the advantage of being dynamic, since previous steps can be repeated 
for individual constructs, should problems occur in later steps.  The ability to include 
sequencing steps at various points in the procedure help to ensure the correctness of the final 
constructs. 
 
The M-PFC system seems to be able to identify true interactions.  When incubated for an 
additional week, no additional interacting partners could be identified, indicating that 
spontaneous growth will not occur for all co-transformations, if incubated for a longer period 
of time.  A trimethoprim concentration of 15µg/ml is also sufficient for screening, with no 
growth occurring at a concentration of 25µg/ml, which is lower than the original 
recommended concentration of 50µg/ml trimethoprim (Singh et al.,  2006).   
 
It is, however, important that M-PFC only be considered a fishing experiment, since the 
protein-protein interactions identified by this method need to be verified by additional 
experiments. Possible procedures could include the Split-Trp protein sensor which is also a 
mycobacterial two-hybrid system.  In this case, should protein interactions occur, growth on a 
medium containing tryptophan will occur.  The Split-Trp method can be applied in both E. 
coli and M. smegmatis (O’Hare et al., 2008).  More diverse techniques for the confirmation of 
these reactions could include Biacore assays and pull-down assays.  Biacore assays provide a 
label-free method to analyse interactions in real time and include determining the kinetics and 
binding strength of interactions (GE Healthcare).  A pull-down assay is an in vitro technique 
whereby a purified, tagged protein will serve as the bait, to be “pulled-down” by a protein 
serving as the prey, should a protein-protein interaction occur (Schechtman et al., 2003).  
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Future experiments to complete the interactome study of the ESAT-6 region 4 of M. 
tuberculosis by means of M-PFC will include screening for protein interactions between 
ESAT-6 region 4 members and the proteins of the other ESAT-6 gene cluster regions.  This 
could also be expanded into a screen of the full genome of M. tuberculosis, as a means to 
determine all interactions of this region and to identify novel substrates.  Since ESAT-6 region 
4 has been shown to be ancestral (Gey van Pittius et al.,  2001), discoveries about this specific 
region will result in a better understanding of the evolution of the ESAT-6 gene cluster 
regions, as well as provide clues to the original function of such a gene cluster region. 
56 
 
4.1.2 The interactions of ESX-4 
 
Many interactions were identified throughout ESX-4, including the expected interaction 
between ESAT-6 (Rv3444) and CFP-10 (Rv3445).  For the fragments of Rv3444 (Rv3444A 
and Rv3444B) and Rv3445 (Rv3445A and Rv3445B) very few interactions were found when 
fused to the pUAB400 vector.  Rv3444 and Rv3445 were originally split into two fragments 
each, because of possible toxic side effects when the entire genes are expressed, but seemed to 
be more toxic when split.  Seven co-transformants, containing at least one split gene each, 
could not be successfully propagated in liquid culture, which could be indicative of toxicity.  
Only interactions of the entire Rv3444 and Rv3445 genes will be discussed further. 
 
Not all interactions could be identified in both directions, which could indicate that some 
refinements are still required in the M-PFC system.  It is possible that interference of the fused 
mDHFR domain could also influence or inhibit the correct folding of the proteins.  The fact 
that there is only one copy of the integrative vector (pUAB400), but possibly multiple copies 
of the episomal vector (pUAB300) present could also explain why some interactions could not 
be found in both directions.  It is also possible that, even though M. smegmatis is a good 
model organism for M. tuberculosis, not all posttranslational modification and protein folding 
events are able to occur correctly.   
 
These interactions can be used to draw interaction maps of ESX-4.  Self-interactions, which 
are indicative of homomultimerization, and interactions which could be identified in both 
directions are indicated in Fig 4.1 and a map of all the interactions of ESX-4 is shown in Fig 
4.2. 
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Figure 4.1 Interaction map of the protein interactions of ESX-4.  Self interactions are 
indicated as dashed lines and interactions between proteins are indicated as solid lines. 
Interactions found in only one direction, as well as interactions of the fragments of Rv3444 
(Rv3444A and Rv3444B) and Rv3445 (Rv3445A and Rv3445B) have been excluded.   
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Figure 4.2 Interaction map of the protein interactions of ESX-4.  Self interactions are 
indicated as dashed lines and interactions between proteins are indicated as solid lines. 
Interactions found in both directions are indicated as solid black lines and interactions found 
in only one direction are indicated in solid grey lines.  Interactions of the fragments of Rv3444 
(Rv3444A and Rv3444B) and Rv3445 (Rv3445A and Rv3445B) have been excluded.   
 
 
These interactions were used to set up a model of the ESX-4 secretion system.  The 
interactions which were found suggest that the components of ESX-4 can assemble into the 
novel type VII secretion system, through which the ESAT-6/CFP-10 complex is secreted (Fig 
4.3).  The interactions found throughout the region also suggest that all gene products 
participate in the formation and function of the ESX secretion machinery (Fig 4.3).  Since 
ESX-4 is ancestral, it represents the most basic components for the functioning of such a 
secretion system.   
59 
 
 
Based on the protein-protein interactions identified by M-PFC, the ESX-4 secretion system 
bears homology to the ESX-1 secretion system.  We hypothesize that ESAT-6 (esxT) and 
CFP-10 (esxU) form a tight complex and are secreted through the pore forming integral 
membrane protein (Rv3448).  The membrane protein ATPase (Rv3447) provides the energy 
for the active transport system.  The region specific alanine and valine rich protein (Rv3446) 
also shows interaction with the membrane protein ATPase, although the function is not 
certain.  Furthermore, the membrane-anchored mycosin protease (Rv3449) shows interaction 
with Rv3448, but the exact function is unknown (Fig 4.3).  
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Figure 4.3 Proposed model of the ESX-4 secretion system, containing all the components 
of ESX-4 and the interactions identified by means of M-PFC.  Protein-protein interactions 
occur throughout the region, with ESAT-6 and CFP-10 forming a tight 1:1 complex, which is 
then hypothesized to be secreted through the pore-forming integral membrane protein 
(Rv3448).  The membrane protein ATPase (Rv3447) provides the energy for this active 
transport and shows interaction with the ESX-4 specific protein, Rv3446.  A possible 
interaction between the membrane anchored mycosin protease (Rv3449) and Rv3448 
(indicated by the dashed arrow) has also been identified, although the exact function is 
unknown. 
 
ESX-4 is the ancestral ESX region of M. tuberculosis.  It also contains the least number of 
genes of all five regions and is not required for in vivo growth of the organism.  However, 
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based on the protein-protein interactions identified by means of M-PFC, the components of 
ESAT-6 region 4 assemble to form the novel type VII secretion system whereby the ESAT-
6/CFP-10 complex is secreted.  It would seem that all components form part of this 
mechanism, although the exact functions of some of the components remain unclear.  A 
comparison of the model of secretion of ESX-4 and the other ESX secretion systems, 
specifically ESX-1, can provide further insights into which components are directly involved 
in pathogenicity, since ESX-4 contains only seven genes, of which one is specific to this 
region.    
62 
 
4.1.3 Comparison of the protein interactions in ESX-4 and ESX-3 
The protein-protein interactions of ESX-3 have previously been elucidated by means of M-
PFC (Table 4.1).  ESX-3 represents a duplication of the ESX gene cluster region.  It contains 
11 genes and had been shown to be required for mycobactin-mediated iron acquisition 
(Siegrist et al., 2009). 
 
ESX-4 contains one gene (Rv3446) which is only found in this region and ESX-3 contains 
five genes not present in ESX-4, namely members of the PE and the PPE families, and genes 
encoding for an AAA+ class ATPase, ABC transporter family signature and a 2 x amino-
terminal transmembrane protein.  Thus, the protein-protein interactions of only six genes 
present in both regions could be compared between ESX-4 and ESX-3.  These include ESAT-
6, CFP-10, eccC (gene split into two due to size), eccD and eccB, as well as MycP.  ESX-3 
contains 25 comparable interactions (Table 4.1) and ESX-4 contains 30 comparable 
interactions (Table 4.2).  When compared, 19 protein-protein interactions were found to be 
identical between the two regions (Table 4.3).  This indicates a definite similarity between the 
protein-protein interactions of ESX-3 and ESX-4, and thus the mechanism of secretion.  It is 
also indicative of a similarity in sensitivity of the M-PFC system when applied to the different 
ESX regions.   
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Table 4.1 Comparable protein interactions of ESX-3.  Protein interactions are indicated by 
an ‘X’, grey blocks represent co-transformations that could not be propagated in liquid culture 
for ESX-4.  (Information kindly supplied by M Newton-Foot) 
 
 
Table 4.2 Comparable protein interactions of ESX-4.  Protein interactions are indicated by 
an ‘X’, grey blocks represent co-transformations that could not be propagated in liquid culture 
for ESX-4.  
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Table 4.3 Overlay of ESX-3/ESX-4 protein interactions, as identified by M-PFC.  
Interactions occurring in both ESX-3 and ESX-4 are indicated by a bold ‘X’, grey blocks 
represent co-transformations that could not be propagated in liquid culture for ESX-4.  Pink 
shading indicates self-interaction and green shading indicates growth for ESX-4 genes in both 
vector combinations. 
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4.2 The construction of genetic knock-outs of ESAT-6 Region 4 in 
Mycobacterium smegmatis 
 
4.2.1 Homologous Recombination Methodology 
A further aim of the investigation was to create a genetic knock-out of ESX-4 in M. smegmatis  
by means of homologous recombination techniques (Parish et al.,  1999).  Homologous 
recombination proved to be an effective technique in generating targeted genetic knock-outs, 
while including selectable and counter-selectable markers to ease in the identification of single 
cross over (SCO) and double cross over (DCO) events.  Sensitivity of these markers might be 
improved by increasing the concentration, since a concentration of 5% sucrose still allows for 
the growth of many blue colonies in the DCO selection step. 
 
4.2.2 The construction of a genetic knock-out of ESX-4 in M. smegmatis 
A targeted genetic knock-out of ESX-4 in M. smegmatis was constructed by means of 
homologous recombination and confirmed by means of PCR screening and sequencing.  No 
differences could be observed between the knock-out and wild type strain in terms of growth 
rate in liquid media, colony morphology on solid media or by microscopy after ZN staining.   
 
The knock-out strain will also be utilised in further comparative studies, which will enable us 
to distinguish phenotypic differences between the knock-out and wild type strains, as well as 
to identify variations in their proteomes, secretomes and metabolomes. 
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CONCLUSION AND FUTURE DIRECTIONS 
  
CHAPTER FIVE 
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5.1 Mycobacterium Protein Fragment Complementation (M-PFC) 
 
M-PFC is a dynamic mycobacterial two-hybrid system, which provides many advantages for 
identifying protein-protein interactions in mycobacteria, whilst overcoming the limitations of 
the classical yeast two-hybrid system.  However, it is important to regard M-PFC as a fishing 
experiment and it is essential that further experimental approaches are applied in order to 
confirm these interactions. 
 
The M-PFC system will also benefit from refinements, such as acquiring a dam(-) E. coli 
strain with blue/white selection for initial transformation steps which would increase the 
likelihood of the desired construct being present when colonies are picked and could, in turn, 
increase chances of finding the construct in the first round of PCR screening.   
 
The protein-protein interactions identified in this study shows that a wide range of interactions 
occurs within ESAT-6 region 4. It also indicates that the components of ESX-4 assemble to 
form the novel type VII secretion system whereby the ESAT-6/CFP-10 complex is secreted.  
It is essential that these findings be confirmed by other techniques in order to set up a robust 
model of the ESX-4 secretion system based only on confirmed interactions.  A comparison of 
the model of secretion of ESX-4 and the other ESX secretion systems, specifically ESX-1, can 
provide further insights into which components are directly involved in pathogenicity, since 
ESX-4 contains only seven genes, of which one is region specific.   
 
The identification of interactions between ESAT-6 region 4 and the other ESAT-6 gene cluster 
regions, as well as a screen of the full genome of M. tuberculosis could lead to discoveries 
about this region and will result in a better understanding of the evolution of the ESAT-6 gene 
cluster regions, as well as provide clues to the original function of these a gene cluster regions. 
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5.2 The construction of genetic knock-outs of ESAT-6 Region 4 in 
Mycobacterium smegmatis 
 
Homologous recombination is an effective method for the construction of targeted genetic 
knock-outs and a knock-out of ESX-4 in M. smegmatis could be obtained.  This also indicated 
that ESX-4 is not essential for the in vivo growth of M. smegmatis.  The knock-out strain also 
showed no difference in growth rate, colony morphology or by microscopy after ZN staining, 
when compared to the wild type strain.  Future metabolomic, secretomic and proteomic 
approaches will provide more data on the function of ESX-4. 
 
A future objective would be to construct a double knock-out of ESX-3 and ESX-4 in M. 
smegmatis, whereby only ESX-1 remains present in the genome.  This will allow for various 
functional studies to be carried out on a M. smegmatis strain containing only ESX-1.  
Individual genes of ESX-1 could then be targeted for knock-out in order to study the function 
of each component of the system.  Finally, all three ESX regions of M. smegmatis could be 
knocked out and, if a viable strain is achieved, further metabolomic, secretomic and proteomic 
studies can be carried out. 
 
In addition, if functional differences are discovered between knock-out strains and the wild 
type strain, the specific region must be reintroduced into the genome by means of knock-in 
techniques in order to restore the original function and satisfy molecular Koch’s postulate.  
The two ESX regions absent from M. smegmatis, but present in M. tuberculosis, namely ESX-
2 and ESX-5 could also be knocked into M. smegmatis and various functional studies carried 
out. 
 
A greater understanding of these immunopathogenically important secretion systems may 
provide valuable clues as to how to interfere with these systems in the pathogen, potentially 
leading to advances in the treatment and prevention of tuberculosis disease. 
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ADDENDUM 
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6.1 Addendum A 
Additional photographic representation of agarose gels used in Mycobacterial Protein 
Fragment Complementation  
 
PCR Screening 
 
 
Figure A.1 PCR screening of Rv3449 to confirm presence of insert in pUAB300, as well 
as orientation. A specific pUAB300 sequencing primer served as the forward primer, while 
the original reverse primer (Table 2.2).  The use of these primers results in a PCR 
amplification product ± 80bp larger than the original amplification product, if the insert is 
present and in the correct orientation.  Should the insert be present, but in the incorrect 
orientation, a PCR amplification product of ± 100bp will be produced.  In the case of Rv3449 
(original product size of ± 1400bp) a product of ± 1500bp is produced in lanes 3,5,7,8,9,10 
and 12, indicating the presence of the insert in the correct orientation.  All pUAB300 ligated 
inserts were screened in this manner.  pUAB400 inserts were screened in a similar manner, but 
a pUAB400 specific sequencing primer served as forward primer. 
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6.2 Addendum B  
Additional photographic representation of agarose gels used in knock-out construction 
 
 
 
Figure B.1 Digest of the Upstream and Downstream regions of Region 4.  The Upstream 
region was digested out of pGEM-T Easy with the restriction enzymes SalI and SfuI (Lane 2).  
The Downstream region was digested out of pGEM-T Easy with the restriction enzymes SfuI 
and HindlII (Lane 3). 
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Figure B.2 Confirmation of disruption element.  Lanes 2 and 3 indicate two samples 
potentially containing the disruption element.  PCR amplification with original Region-4 
Upstream forward primer and Downstream reverse primer (Table 2.3) results in a PCR 
product of ± 1400bp, confirming the presence of the disruption element. 
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Figure B.3 Digest of p2NIL:R4 with PacI.  Two p2NIL mutants containing the disruption 
element were digested with PacI.  Lanes 2 and 3 contain the cut plasmid of the first sample 
and lanes 5 and 6 contain the cut plasmid of the second sample.  Lanes 4 and 7 contain uncut 
plasmid.   
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6.3 Addendum C 
 
6.3.1 Preparation of Electro competent E. coli 
 
6.3.1.1 E. coli K12 ER2925 
For the first round of M-PFC E. coli transformations the dam negative (-) strain K12 ER2925 
was utilised.  It was essential to use a strain with dam negative properties in order to prevent 
methylation of the restriction site. 
 
Competent cells were inoculated into LB media containing 25µg/ml chloramphenicol and 
grown overnight at 37°C with shaking until an OD600 of between 0.6 and 0.8 was reached.  All 
subsequent steps were carried out under icy cold conditions. 
 
6.3.1.2 E. coli JM109 
All E.coli transformations for knock-out construction were carried out in E. coli strain JM109, 
which enables blue/white colony selection in the presence of X-gal.  
 
Competent cells were inoculated into LB media containing 10µg/ml tetracycline and grown 
overnight at 37°C with shaking until an OD600 of between 0.6 and 0.8 was reached.  All 
subsequent steps were carried out under icy cold conditions. 
 
6.3.1.3 General instructions 
Cells were harvested in a GSA rotor for 10 minutes at 5000 rpm and re-suspended in a volume 
of ice-cold 10% glycerol equal to the original culture volume and washed twice at 5000 rpm.  
All cells were then pooled in a 50ml tube and re-suspended in 10% glycerol.  The cells were 
washed once in a SS34 rotor for 15 minutes at 3000 rpm and re-suspended in 10% glycerol, 
using a volume of 2ml 10% glycerol per initial culture. 
 
Aliquots of 100µl were transferred to sterile 1.5ml tubes and frozen in a liquid nitrogen bath.  
Cells were stored at -80°C. 
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6.3.2 Preparation of Electro competent M. smegmatis 
M. smegmatis mc2155 was used for all mycobacterial transformations.  100µl electro 
competent M. smegmatis was inoculated into 10ml 7H9 containing either Kanamycin 
(25µg/ml) for M. smegmatis containing the pUAB400 integrated plasmid (M-PFC), or lacking 
antibiotic, in the case of wild type M. smegmatis.  The 10ml starter cultures were incubated 
overnight at 37°C with shaking. 
 
One millilitre  M. smegmatis from the 10ml starter culture was inoculated into 100ml 7H9 
containing either Kanamycin (25µg/ml) for M. smegmatis containing the pUAB400 integrated 
plasmid (M-PFC), or lacking antibiotic, in the case of wild type M. smegmatis.  Cultures were 
grown overnight at 37°C with shaking until an OD600 of between 0.5 and 1.0 was reached.  All 
subsequent steps were carried out under icy cold conditions.  
 
The culture was transferred to 50ml tubes and the cells harvested in a SS34 rotor at 4000 rpm 
for 15 minutes.  Cells were re-suspended in 10% glycerol and washed twice at 4000 rpm for 
15 minutes.  Cells were pooled in one 50ml tube and washed once at 4000 rpm for 10 minutes.  
Cells were re suspended in 2ml 10% glycerol.  Electro competent cells could be used 
immediately, or frozen in a liquid nitrogen bath and stored at -80°C.   
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6.4 Addendum D 
Examples of M-PFC screening 
 
Figure D.1 Example of M-PFC screening on plates containing kanamycin, hygromycin 
and trimethoprim (15µg/ml).  
 
 
Figure D.1 Example of M-PFC screening on plates containing kanamycin, hygromycin 
and trimethoprim (20µg/ml).  
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